DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (NYSE Amex: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced consolidated results for the second quarter of 2011 and for the six-month period ended June 30, 2011. Neoprobe revenues for the second quarter of 2011 were $3.2 million compared to $2.5 million for the second quarter of 2010. Year-to-date revenues for the six-month period ended June 30, 2011 were $6.0 million compared to $5.2 million for the same period of 2010. Neoprobe second quarter 2011 operating expenses were $4.4 million compared to $2.7 million for the second quarter of 2010. Operating expenses for the six-month period ended June 30, 2011 were $9.9 million compared to $6.2 million for the same period of 2010. Neoprobe loss from operations for the second quarter of 2011 was $2.2 million compared to $929,000 for the second quarter of 2010. Neoprobe loss from operations for the six-month period ended June 30, 2011 was $5.7 million, compared to $2.7 million for the same period of 2010.
